Literature DB >> 22740797

Cancer Pain Management and Bone Metastases: An Update for the Clinician.

Guido Schneider1, Raymond Voltz, Jan Gaertner.   

Abstract

Breast cancer patients with bone metastases often suffer from cancer pain. In general, cancer pain treatment is far from being optimal for many patients. To date, morphine remains the gold standard as first-line therapy, but other pure μ agonists such as hydromorphone, fentanyl, or oxycodone can be considered. Transdermal opioids are an important option if the oral route is impossible. Due to its complex pharmacology, methadone should be restricted to patients with difficult pain syndromes. The availability of a fixed combination of oxycodone and naloxone is a promising development for the reduction of opioid induced constipation. Especially bone metastases often result in breakthrough pain episodes. Thus, the provision of an on-demand opioid (e.g., immediate-release morphine or rapid-onset fentanyl) in addition to the baseline (regular) opioid therapy (e.g., sustained-release morphine tablets) is mandatory. Recently, rapid onset fentanyls (buccal or nasal) have been strongly recommended for breakthrough cancer pain due to their fast onset and their shorter duration of action. If available, metamizole is an alternative non-steroid-anti-inflammatory-drug. The indication for bisphosphonates should always be checked early in the disease. In advanced cancer stages, glucocorticoids are an important treatment option. If bone metastases lead to neuropathic pain, coanalgetics (e.g., pregabalin) should be initiated. In localized bone pain, radiotherapy is the gold standard for pain reduction in addition to pharmacologic pain management. In diffuse bone pain radionuclids (such as samarium) can be beneficial. Invasive measures (e.g., neuroaxial blockage) are rarely necessary but are an important option if patients with cancer pain syndromes are refractory to pharmacologic management and radiotherapy as described above. Clinical guidelines agree that cancer pain management in incurable cancer is best provided as part of a multiprofessional palliative care approach and all other domains of suffering (psychosocial, spiritual, and existential) need to be carefully addressed («total pain»).

Entities:  

Year:  2012        PMID: 22740797      PMCID: PMC3376368          DOI: 10.1159/000338579

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN: 1661-3791            Impact factor:   2.860


  61 in total

Review 1.  Foundations of opioid risk management.

Authors:  Nathaniel P Katz; Edgar H Adams; James C Benneyan; Howard G Birnbaum; Simon H Budman; Ronald W Buzzeo; Daniel B Carr; Theodore J Cicero; Douglas Gourlay; James A Inciardi; David E Joranson; James Kesslick; Stephen D Lande
Journal:  Clin J Pain       Date:  2007-02       Impact factor: 3.442

2.  Control of pain in adults with cancer: summary of SIGN guidelines.

Authors:  P J Cormie; M Nairn; J Welsh
Journal:  BMJ       Date:  2008-11-05

3.  Drug interactions in palliative care--it's more than cytochrome P450.

Authors:  Jan Gaertner; Klaus Ruberg; Grit Schlesiger; Sebastian Frechen; Raymond Voltz
Journal:  Palliat Med       Date:  2011-07-07       Impact factor: 4.762

Review 4.  Oral methadone for chronic noncancer pain: a systematic literature review of reasons for administration, prescription patterns, effectiveness, and side effects.

Authors:  Juan Alberto Sandoval; Andrea D Furlan; Angela Mailis-Gagnon
Journal:  Clin J Pain       Date:  2005 Nov-Dec       Impact factor: 3.442

5.  An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain.

Authors:  A Caraceni; R K Portenoy
Journal:  Pain       Date:  1999-09       Impact factor: 6.961

6.  Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.

Authors:  Sebastiano Mercadante; Giampiero Porzio; Patrizia Ferrera; Fabio Fulfaro; Federica Aielli; Lucilla Verna; Patrizia Villari; Corrado Ficorella; Vittorio Gebbia; Salvatore Riina; Alessandra Casuccio; Salvatore Mangione
Journal:  Eur J Pain       Date:  2008-03-18       Impact factor: 3.931

Review 7.  Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.

Authors:  Y-F Chen; P Jobanputra; P Barton; S Bryan; A Fry-Smith; G Harris; R S Taylor
Journal:  Health Technol Assess       Date:  2008-04       Impact factor: 4.014

Review 8.  Neuraxial pain relief for intractable cancer pain.

Authors:  Paul A Sloan
Journal:  Curr Pain Headache Rep       Date:  2007-08

Review 9.  Palliative radiotherapy trials for bone metastases: a systematic review.

Authors:  Edward Chow; Kristin Harris; Grace Fan; May Tsao; Wai M Sze
Journal:  J Clin Oncol       Date:  2007-04-10       Impact factor: 44.544

10.  A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain.

Authors:  Sam H Ahmedzai; Friedemann Nauck; Gil Bar-Sela; Björn Bosse; Petra Leyendecker; Michael Hopp
Journal:  Palliat Med       Date:  2011-09-21       Impact factor: 4.762

View more
  11 in total

1.  Bone Metastasis in Breast Cancer.

Authors:  Ingo J Diel
Journal:  Breast Care (Basel)       Date:  2012-04-24       Impact factor: 2.860

Review 2.  Bone Pain and Muscle Weakness in Cancer Patients.

Authors:  Daniel P Milgrom; Neha L Lad; Leonidas G Koniaris; Teresa A Zimmers
Journal:  Curr Osteoporos Rep       Date:  2017-04       Impact factor: 5.096

Review 3.  Cancer pain management: what's new?

Authors:  Jan Gaertner; Christine Schiessl
Journal:  Curr Pain Headache Rep       Date:  2013-04

Review 4.  Prevention and treatment of bone fragility in cancer patient.

Authors:  Silva Ottanelli
Journal:  Clin Cases Miner Bone Metab       Date:  2015-10-26

5.  Use of paclitaxel carried in lipid core nanoparticles in patients with late-stage solid cancers with bone metastases: Lack of toxicity and therapeutic benefits.

Authors:  Carolina G Vital; Raul C Maranhão; Fatima R Freitas; Brigitte M Van Eyll; Silvia R Graziani
Journal:  J Bone Oncol       Date:  2022-04-20       Impact factor: 4.491

6.  Safety and efficacy of naldemedine in cancer patients with opioid-induced constipation: a pooled, subgroup analysis of two randomised controlled studies.

Authors:  Iwao Osaka; Hiroto Ishiki; Takaaki Yokota; Yukio Tada; Hiroki Sato; Masaharu Okamoto; Eriko Satomi
Journal:  ESMO Open       Date:  2019-07-31

7.  Randomized Double-Blind Trial of Pregabalin Versus Placebo in Conjunction With Palliative Radiotherapy for Cancer-Induced Bone Pain.

Authors:  Marie Fallon; Peter J Hoskin; Lesley A Colvin; Susan M Fleetwood-Walker; Douglas Adamson; Anthony Byrne; Gordon D Murray; Barry J A Laird
Journal:  J Clin Oncol       Date:  2015-12-07       Impact factor: 44.544

Review 8.  [Expert consensus on the diagnosis and treatment of bone metastasis in lung cancer (2014 version)].

Authors:  Yan Sun; Zhongzhen Guan; Meilin Liao; Xin Yu; Changli Wang; Jie Wang; Xiaohui Niu; Yuankai Shi; Xiuyi Zhi; Yunpeng Liu; Mengzhong Liu; Yiping Zhang; Yue Yang; Jingnan Shen; Gongyan Chen; Qinghua Zhou; Caicun Zhou; Qisen Guo; Lili Tang; Jianchun Duan; Jun Liang; Yingjian Zhang; Ying Cheng
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2014-02

9.  circStrn3 is involved in bone cancer pain regulation in a rat model.

Authors:  Yiwen Zhang; Xiaoxia Zhang; Zumin Xing; Shuyi Tang; Hanwen Chen; Zhongqi Zhang; Jiyuan Li; Yalan Li
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2020-05-26       Impact factor: 3.848

10.  The Challenges of Managing Bone Pain in Cancer.

Authors:  Carenza Glithero
Journal:  Ulster Med J       Date:  2020-02-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.